VOR vs NKTR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NKTR Captures Institutional Edge (2โ2 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nektar Therapeutics (NKTR) driven by superior Valuation, Options & Structure while VOR counters with relative strength in Growth & Margin, Momentum & Technical. Fundamentally, VOR trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus NKTR at 34.0x Forward P/E and -239.3% operating margin (-9.3% YoY). In options structure, VOR sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against NKTR sits in BREAKDOWN (5th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VOR | NKTR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.2B | $1.3B | Larger Scale | NKTR |
| Trailing P/E Ratio Valuation | 0.1x | 34.0x | Lower Multiple | VOR |
| Forward P/E Ratio Valuation | N/M | 34.0x | Lower Multiple | NKTR |
| Revenue Growth (YoY) Growth | +0.0% | -9.3% | Higher Growth | VOR |
| Operating Margin (TTM) Profitability | 0.0% | -239.3% | Higher Margin | VOR |
| Net Profit Margin Profitability | 0.0% | -287.8% | Higher Margin | VOR |
| Return on Equity (ROE) Capital Efficiency | -125.4% | -35.8% | Higher ROE | NKTR |
| 52-Week Range Position Momentum | 65% ($6โ$26) | 4% ($33โ$109) | Stronger Trend | VOR |
| Beta / 30D Volatility Risk Regime | 1.91ฮฒ ยท 61% Vol | 1.10ฮฒ ยท 48% Vol | Lower Realized Risk | NKTR |
| Unified Institutional Score Composite Signal | 57.8 / 100 (HOLD) | 61.1 / 100 (BUY) | Higher Composite | NKTR |